Ander Matheu Fernández-rekin lankidetzan egindako argitalpenak (11)

2022

  1. Senescence plays a role in myotonic dystrophy type 1

    JCI insight, Vol. 7, Núm. 19

  2. Targeting Myotonic Dystrophy Type 1 with Metformin

    International Journal of Molecular Sciences, Vol. 23, Núm. 5

2020

  1. Leukocyte telomere length in patients with myotonic dystrophy type I: a pilot study

    Annals of Clinical and Translational Neurology, Vol. 7, Núm. 1, pp. 126-131

  2. Myotonic Dystrophy type 1 cells display impaired metabolism and mitochondrial dysfunction that are reversed by metformin

    Aging, Vol. 12, Núm. 7, pp. 6260-6275

2019

  1. T cells and immune functions of plasma extracellular vesicles are differentially modulated from adults to centenarians

    Aging, Vol. 11, Núm. 22, pp. 10723-10741

2018

  1. Cancer phenotype in myotonic dystrophy patients: Results from a meta-analysis

    Muscle and Nerve, Vol. 58, Núm. 4, pp. 517-522

2016

  1. Cancer risk in DM1 is sex-related and linked to miRNA-200/141 downregulation

    Neurology, Vol. 87, Núm. 12, pp. 1250-1257

  2. Identification and Characterization of the Dermal Panniculus Carnosus Muscle Stem Cells

    Stem Cell Reports, Vol. 7, Núm. 3, pp. 411-424

2015

  1. Muscle wasting in myotonic dystrophies: A model of premature aging

    Frontiers in Aging Neuroscience, Vol. 7, Núm. JUN

2014

  1. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool

    Neuro-Oncology, Vol. 16, Núm. 4, pp. 520-527

2012

  1. Oncogenicity of the developmental transcription factor Sox9

    Cancer Research, Vol. 72, Núm. 5, pp. 1301-1315